Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Jatinder Singh, PhD"'
Autor:
Dong-Wan Kim, MD, PhD, Shirish Gadgeel, MD, Scott N. Gettinger, MD, Gregory J. Riely, MD, PhD, Geoffrey R. Oxnard, MD, Tarek Mekhail, MD, Peter Schmid, MD, PhD, Afshin Dowlati, MD, Rebecca S. Heist, MD, MPH, Antoinette J. Wozniak, MD, Jatinder Singh, PhD, Edward Cha, MD, PhD, Jessica Spahn, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100367- (2022)
Introduction: Alectinib is a preferred first-line treatment option for advanced ALK-positive NSCLC. Combination regimens of alectinib with immune checkpoint inhibitors are being evaluated for synergistic effects. Methods: Adults with treatment-naive,
Externí odkaz:
https://doaj.org/article/ef3f254cb8784bd19307c98d578cc81c